PubMed · 42683025
Clinical Benefit of Pembrolizumab in Lynch Syndrome-Associated Advanced Ovarian Cancer With Germline MSH6 Variant: A Case Report.
Abstract
This case highlights the importance of genetic evaluation during treatment in young patients with advanced ovarian cancer. Lynch syndrome caused by a germline MSH6 pathogenic variant was diagnosed during first-line maintenance therapy, and pembrolizumab achieved a durable response in recurrent disease.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Tomomi Yokozawa, Sayako Nakagawa, Yukio Suzuki, Aya Tokinaga-Uchiyama, Katsuyuki Konnai, Hiroto Narimatsu, Yukihiko Hiroshima, Haruya Saji. 2026-08-31. Clinical Benefit of Pembrolizumab in Lynch Syndrome-Associated Advanced Ovarian Cancer With Germline MSH6 Variant: A Case Report.. https://doi.org/10.1002/ccr3.73444
Cite the original work for its findings. Save a collection to share your selection of sources.